Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: Results of a randomized, double-blind, placebo-controlled study

Journal of Clinical Oncology

Volumn 28, Issue 24, 2010, Pages 3824-3829

  Kang, Yoon Koo ^a   Lee, Sung Sook ^a   Yoon, Dok Hyun ^a   Lee, So Young ^a   Chun, Young Ju ^a   Kim, Min Sun ^a   Ryu, Min Hee ^a   Chang, Heung Moon ^a   Lee, Jae Lyun ^a   Kim, Tae Won ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CISPLATIN; DOCETAXEL; PLACEBO; PYRIDOXINE; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; VITAMIN B COMPLEX;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HAND FOOT SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; ANALYSIS OF VARIANCE; CHEMICALLY INDUCED DISORDER; HAND DISEASE; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; SKIN DISEASE; SYNDROME; TREATMENT FAILURE;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; DOUBLE-BLIND METHOD; FEMALE; FLUOROURACIL; FOOT DERMATOSES; HAND DERMATOSES; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PYRIDOXINE; SYNDROME; TREATMENT FAILURE; VITAMIN B COMPLEX; YOUNG ADULT;

EID: 77956257728     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.29.1807     Document Type: Article

References (33)

1. Lipworth AD, Robert C, Zhu AX: Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): Focus on sorafenib and sunitinib. Oncology 77:257-271, 2009
2. Baack BR, Burgdorf WH: Chemotherapy-induced acral erythema. J Am Acad Dermatol 24:457-461, 1991
3. Abushullaih S, Saad ED, Munsell M, et al: Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: A single-institution experience. Cancer Invest 20:3-10, 2002 (Pubitemid 34151055)
4. Nagore E, Insa A, Sanmartin O: Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome: Incidence, recognition and management. Am J Clin Dermatol 1:225-234, 2001
5. Lokich JJ, Moore C: Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 101:798-799, 1984
6. Herzig RH, Wolff SN, Lazarus HM, et al: High-dose cytosine arabinoside therapy for refractory leukemia. Blood 62:361-369, 1983 (Pubitemid 13036086)
7. Toxicity of fluorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors: Meta-Analysis Group In Cancer. J Clin Oncol 16:3537-3541, 1998
8. Heo YS, Chang HM, Kim TW, et al: Hand-foot syndrome in patients treated with capecitabine-containing combination chemotherapy. J Clin Pharmacol 44:1166-1172, 2004 (Pubitemid 39202461)
9. Vukelja SJ, Lombardo FA, James WD, et al: Pyridoxine for the palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 111:688-689, 1989
10. Fabian CJ, Molina R, Slavik M, et al: Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest New Drugs 8:57-63, 1990 (Pubitemid 20087245)
11. Gordon KB, Tajuddin A, Guitart J, et al: Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer 75:2169-2173, 1995
12. Portal I, Cardenal F, Garcia-del-Muro X: Etoposide-related acral erythema. Cancer Chemother Pharmacol 34:181, 1994 (Pubitemid 24157986)
13. Vukelja SJ, Baker WJ, Burris HA, et al: Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with Taxotere. J Natl Cancer Inst 85:1432-1433, 1993 (Pubitemid 23264353)
14. Mortimer JE, Lauman MK, Tan B, et al: Pyridoxine treatment and prevention of hand-and-foot syndrome in patients receiving capecitabine. J Oncol Pharm Pract 9:161-166, 2003 (Pubitemid 37461547)
15. Vail DM, Chun R, Thamm DH, et al: Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: A randomized, double-blind clinical trial using a canine model. Clin Cancer Res 4:1567-1571, 1998 (Pubitemid 28265245)
16. Beveridge R, Kales A, Bider R, et al: Pyridoxine (B6) and amelioration of hand/foot syndrome. Proc Am Soc Clin Oncol 9:102a, 1990 (abstr 393)
17. Wiernik PH, Yeap B, Vogl SE, et al: Hexamethylmelamine and low or moderate dose cisplatin with or without pyridoxine for treatment of advanced ovarian carcinoma: A study of the Eastern Cooperative Oncology Group. Cancer Invest 10:1-9, 1992
18. Yoshimoto N, Yamashita T, Fujita T, et al: Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer. Breast Cancer [epub ahead of print on September 30, 2009]
19. Hau P, Fabel K, Baumgart U, et al: Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer 100:1199-1207, 2004 (Pubitemid 38325948)
20. Von Gruenigen VE, Frasure H, Fusco N, et al: A double-blind randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin hydrochloride-related palmarplantar erythrodysesthesia. J Clin Oncol 27:300s, 2009 (suppl; abstr 5594)
21. Eich D, Scharffetter-Kochanek K, Eich HT, et al: Acral erythrodysesthesia syndrome caused by intravenous infusion of docetaxel in breast cancer. Am J Clin Oncol 25:599-602, 2002 (Pubitemid 35453668)
22. Chu CY, Yang CH, Yang CY, et al: Fixed erythrodysaesthesia plaque due to intravenous injection of docetaxel. Br J Dermatol 142:808-811, 2000
23. Nadella P, Shapiro C, Otterson GA, et al: Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies. J Clin Oncol 20:2616-2623, 2002 (Pubitemid 34575633)
24. Smorenburg CH, Sparreboom A, Bontenbal M, et al: Combination chemotherapy of the taxanes and antimetabolites: Its use and limitations. Eur J Cancer 37:2310-2323, 2001 (Pubitemid 33097466)
25. Milano G, Etienne-Grimaldi MC, Mari M, et al: Candidate mechanisms for capecitabine-related hand-foot syndrome. Br J Clin Pharmacol 66:88-95, 2008 (Pubitemid 351822156)
26. Yen-Revollo JL, Goldberg RM, McLeod HL: Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines? Clin Cancer Res 14:8-13, 2008
27. Saif MW, Diasio R: Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency? Clin Colorectal Cancer 5:359-362, 2006
28. Gyorgy P, Eckardt R: Vitamin B6 and skin lesions in rats. Nature 144:512, 1939
29. Drake RD, Lin WM, King M, et al: Oral dexamethasone attenuates Doxil-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies. Gynecol Oncol 94:320-324, 2004 (Pubitemid 39024533)
30. Brown J, Burck K, Black D, et al: Treatment of cytarabine acral erythema with corticosteroids. J Am Acad Dermatol 24:1023-1025, 1991
31. Zimmerman GC, Keeling JH, Burris HA, et al: Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent. Arch Dermatol 131:202-206, 1995
32. Lin EH, Curley SA, Crane CC, et al: Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: Potential benefits and COX-2 as the common mediator in pain, toxicities and survival? Am J Clin Oncol 29:232-239, 2006 (Pubitemid 44270930)
33. Kara IO, Sahin B, Erkisi M: Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction. Breast 15:414-424, 2006